Advarra

AUGUST 31, 2022

Tools or special sharp containers to remove the needle and replace with a fresh and already capped needle. All potentially infectious sharps must be disposed of in a biohazard sharps container immediately after use without recapping. The container can be a rigid plastic container (e.g., A recapping tool.

Production 52

Production Biohazard Biohazard Containment 52

Worldwide Clinical Trials

JUNE 15, 2022

These therapies can have mechanisms that could expose people to biological or biohazardous agents, so therapies must be closely monitored and contained during transport, storage, and administration. Institutional Biosafety Committees (IBC) assess the risk of gene therapies to public health or the environment.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

Advarra

OCTOBER 26, 2023

Controlled Environment and IP Containment The potential for a release, and the risk associated with a genetically engineered IP, are part of the IBC’s assessment purview under National Institutes of Health (NIH) Guidelines. The containment must then prevent spills or leaks if the IP is dropped. Size matters.

Production 52

Production Containment Biohazard Biohazard 52

Cloudbyz

APRIL 9, 2023

Here are some ways to bring sustainability into clinical trial management: Reduce waste: Clinical trials generate a significant amount of waste, including packaging materials, medical equipment, and biohazardous waste. For example, using reusable containers for shipping materials can reduce the amount of packaging waste.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Biohazard 52